Table 2 LB-RECIST and radiological RECISTv1.1 in the cohort

From: Personalized circulating tumor DNA dynamics inform survival and response to immune checkpoint blockade in recurrent/metastatic head and neck cancer

LB-RECIST group

Definition

N (%) LB-RECIST

Patients

RECIST v1.1

N (%)

Patients

1

D -> D

9/16 (56)

02, 03, 06, 07, 09, 13, 14, 19, 26

PD

8/16 (50)

02, 03, 07, 09, 13, 14, 15, 26

2

D -> U

4/16 (25)

08, 10, 20, 25

SD

2/16 (12)

06, 19

3

U -> D

1/16 (6)

15

PR

4/16 (25)

10, 18, 20, 25

4

U -> U

2/16 (12)

18, 23

CR

2/16 (12)

08, 23

  1. Group 1: Patients with detectable ctDNA which remains detectable after therapy; Group 2: Patients with detectable ctDNA which became undetectable after therapy; Group 3: Patients with undetectable ctDNA which became detectable after therapy; Group 4: Patients with undetectable ctDNA which remained undetectable after therapy. D Detectable, U Undetectable25. RECIST v1.1 was able to be applied in 14 cases. For two patients, imaging was not available, and clinical assessment was used. PD progressive disease, SD stable disease, PR partial response, CR complete response.
Back to article page